|
US2008175872A1
|
|
Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
|
|
KR20090053892A
|
|
Ophthalmic solutions
|
|
BRPI0515761A
|
|
osmotic device containing amantadine and an osmotic salt
|
|
ES2296454A1
|
|
LASER PERFORATION SYSTEM AND METHOD.
|
|
EP1714641A2
|
|
Osmotic device containing a venlafaxine salt and a salt having a common ion
|
|
WO2006056144A2
|
|
Osmotic device containing licofelone
|
|
US7569794B2
|
|
Laser drilling system and method
|
|
EP1629835A2
|
|
Breakable, controlled release device comprising a preformed passage
|
|
EP1600156A2
|
|
Combination treatment for impaired motor function in parkinson's disease
|
|
US7147870B2
|
|
Osmotic device containing pseudoephedrine and an H1 antagonist
|
|
EP1764180A1
|
|
Laser drilling system
|
|
EP1461018A2
|
|
Dual controlled release dosage form
|
|
AU2002351655A1
|
|
Device for release of a drug containing oseltamivir and a h1 antagonist
|
|
US6809288B2
|
|
Laser drilling system and method
|
|
AU2002231570A1
|
|
Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
|
|
US6753011B2
|
|
Combined diffusion/osmotic pumping drug delivery system
|
|
US6605302B2
|
|
Drug delivery device containing oseltamivir and an H1 antagonist
|
|
US6676933B2
|
|
Pharmaceutical composition containing mosapride and pancreatin
|
|
US6458808B1
|
|
Pharmaceutical composition for the treatment of cognitive cerebrovascular disease
|
|
US6599532B2
|
|
Osmotic device containing alprazolam and an antipsychotic agent
|
